I am a
Home I AM A Search Login

Papers of the Week

2020 Apr

CNS Spectr



112 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (P302): Efficacy and Safety of Extended-Release Viloxazine in Adolescents with ADHD.


Nasser A, Hull JT, Chowdhry FA, Adewole T, Liranso T, Schwabe S
CNS Spectr. 2020 Apr; 25(2):272-273.
PMID: 32331087.


SPN-812 (extended-release viloxazine) is a structurally distinct, bicyclic, Serotonin Norepinephrine Modulating Agent (SNMA) in development as a treatment for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. This Phase 3, randomized, double-blind study (P302) evaluated the efficacy and safety of once-daily SPN-812 at doses of 200 and 400 mg compared to placebo in adolescents ages 12-17yrs with ADHD.